147 related articles for article (PubMed ID: 36635156)
1. Biology and genetics of acquired and congenital melanocytic naevi.
Maher NG; Scolyer RA; Colebatch AJ
Pathology; 2023 Mar; 55(2):169-177. PubMed ID: 36635156
[TBL] [Abstract][Full Text] [Related]
2. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
[TBL] [Abstract][Full Text] [Related]
3. Defining the Molecular Genetics of Dermoscopic Naevus Patterns.
Tan JM; Tom LN; Soyer HP; Stark MS
Dermatology; 2019; 235(1):19-34. PubMed ID: 30332666
[TBL] [Abstract][Full Text] [Related]
4. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
[TBL] [Abstract][Full Text] [Related]
5. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
[TBL] [Abstract][Full Text] [Related]
6. Massively parallel sequencing analysis of benign melanocytic naevi.
Lozada JR; Geyer FC; Selenica P; Brown D; Alemar B; Merghoub T; Berger MF; Busam KJ; Halpern AC; Weigelt B; Reis-Filho JS; Hollmann TJ
Histopathology; 2019 Jul; 75(1):29-38. PubMed ID: 30791119
[TBL] [Abstract][Full Text] [Related]
7. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
8. Dysplastic/Clark naevus in the era of molecular pathology.
Mesbah Ardakani N
Australas J Dermatol; 2019 Aug; 60(3):186-191. PubMed ID: 30854639
[TBL] [Abstract][Full Text] [Related]
9. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
[TBL] [Abstract][Full Text] [Related]
10. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
11. Does the gene matter? Genotype-phenotype and genotype-outcome associations in congenital melanocytic naevi.
Polubothu S; McGuire N; Al-Olabi L; Baird W; Bulstrode N; Chalker J; Josifova D; Lomas D; O'Hara J; Ong J; Rampling D; Stadnik P; Thomas A; Wedgeworth E; Sebire NJ; Kinsler VA
Br J Dermatol; 2020 Feb; 182(2):434-443. PubMed ID: 31111470
[TBL] [Abstract][Full Text] [Related]
12. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
[TBL] [Abstract][Full Text] [Related]
13. Spitz melanocytic tumours - a review.
Yeh I; Busam KJ
Histopathology; 2022 Jan; 80(1):122-134. PubMed ID: 34958498
[TBL] [Abstract][Full Text] [Related]
14. BRAF and NRAS mutations in spitzoid melanocytic lesions.
Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB
Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476
[TBL] [Abstract][Full Text] [Related]
15. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
[TBL] [Abstract][Full Text] [Related]
16. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.
Tan JM; Lin LL; Lambie D; Flewell-Smith R; Jagirdar K; Schaider H; Sturm RA; Prow TW; Soyer HP
JAMA Dermatol; 2015 Apr; 151(4):417-21. PubMed ID: 25607474
[TBL] [Abstract][Full Text] [Related]
17. Melanocytic naevi clustered on normal background skin.
Torchia D
Clin Exp Dermatol; 2015 Apr; 40(3):231-7. PubMed ID: 25703021
[TBL] [Abstract][Full Text] [Related]
18. Melanocytic naevi, melanocytomas and emerging concepts.
Yeh I
Pathology; 2023 Mar; 55(2):178-186. PubMed ID: 36642570
[TBL] [Abstract][Full Text] [Related]
19. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
Urso C
Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
[TBL] [Abstract][Full Text] [Related]
20. Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification.
Moreno S; Maiques O; Barcelo C; Romero M; Santacana M; Gómez I; Cuevas D; Velasco A; Vea A; Macia A; Boix R; Valls J; Gatius S; Canti C; Matias-Guiu X; Soria X; Marti RM
Acta Derm Venereol; 2021 Nov; 101(11):adv00597. PubMed ID: 34643739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]